Healthcare Professional Educational Material:

Information Material for Healthcare Professionals Prescribing Olumiant® (baricitinib)

This document contains important information to assist the initial discussion with your patients when prescribing Olumiant. It should be read in conjunction with the enclosed Physician Prescribing Information (PPI).

Olumiant is a selective and reversible JAK1/2 inhibitor indicated for the treatment of atopic dermatitis

The background information and points for discussion here provide context and appropriate risk management for key safety aspects of the prescribing information, namely:

- **Infections**
- **Changes in lipid parameters**
- **Venous thromboembolic events**
- **Pregnancy and breast feeding**

As part of the initial discussion with your patients, please:

- Provide a **Patient Alert Card** to each patient and explain that it contains important information they should be aware of before and during treatment with Olumiant.
- Advise them that the Card should be read in conjunction with the **Patient Information Leaflet.**

Infections

Olumiant increases the potential risk of infections, and viral reactivation.

It is important to instruct patients to seek immediate medical attention if signs or symptoms suggesting infection appear, in order to ensure rapid evaluation and appropriate treatment.

If an infection develops, monitor the patient carefully and:

- Temporarily interrupt Olumiant in case of herpes zoster infection or for any infection that is not responding to standard therapy. Do not resume Olumiant treatment until the infection resolves.
- Screen patients to rule out active tuberculosis and active viral hepatitis before starting Olumiant.
- Do not use live, attenuated vaccines during, or immediately prior to, Olumiant therapy.

Changes in Lipid Parameters

In AD clinical trials, increases in total cholesterol, LDL cholesterol and HDL cholesterol were observed at 12 weeks. Mean total and LDL cholesterol increased through week 52. The long term consequences of these changes are unknown.

As a result of these considerations, it is important to:

- Assess lipid parameters approximately 12 weeks following initiation of Olumiant therapy.
- Manage patients according to clinical guidelines for hyperlipidaemia thereafter.
- Correct elevations in LDL cholesterol with statin treatment if necessary

Venous Thromboembolism

Events of deep venous thrombosis (DVT) and pulmonary embolism (PE) have been reported in patients receiving Olumiant. Olumiant should be used with caution in patients with risk factors for DVT/PE, such as older age, obesity, a medical history of DVT/PE, or patients undergoing surgery and immobilisation. If clinical features of DVT/PE occur, Olumiant treatment should be discontinued and patients shouldbe evaluated promptly, followed by appropriate treatment.

As a result, it is important to advise patients to inform you immediately if any of the following symptoms are experienced:

- Swelling or pain in one leg
- Warmth or redness in one leg
- Shortness of breath which is unexpected
- Rapid breathing
- Chest pain

Pregnancy and Breast Feeding

Please discuss these points with your female patients if they are of child bearing potential:

- **Olumiant must not be used during pregnancy.** There is insufficient experience with Olumiant at this time to determine whether it can be safely used in pregnancy.
- **Olumiant should not be used in women who are breast feeding or intend to breast feed.** As there is no information on the excretion of Olumiant into human milk, it is unknown if it is safe to use during breast feeding.

As a result, it is important to:

- **Ask** patients if they are, might be, or intend to become pregnant, or are breast feeding prior to prescribing Olumiant. If a planned pregnancy is considered, baricitinib treatment should be stopped.
- **Advise** women to use effective contraception both during treatment and for at least 1 week after discontinuing treatment, taking into account the short half-life of Olumiant.
- **Advise** patients to inform you immediately if they think they could be pregnant or if pregnancy is confirmed in order to facilitate the appropriate discussions on the potential risks.

Background pre-clinical safety information

As described in sections 4.6 and 5.3 of the PPI, animal studies showed reduced foetal growth and produced skeletal malformations at exposures approximately10 times the human exposure.

As there are no adequate data on the use of Olumiant in human pregnancy, the implications of these non-clinical findings on use in women are not known. Therefore, the advice provided on use in pregnancy is given as a precautionary measure.

Reporting of suspected adverse reactions

Healthcare professionals are asked to report any suspected adverse reactions. Adverse events can be reported directly to the Ministry of Health using the adverse events digital form for adverse events reporting, that is located on the Ministry of Health home page: www.health.gov.il , or by entering the link:

https://sideeffects.health.gov.il

Side effects can also be reported to Eli Lilly by email: report_ilmail-ae@lilly.com.

This brochure content was approved according to the guidelines of the ministry of health on April 2021